Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New laser zaps dry eye by targeting blood vessels on eyelids

NCT ID NCT04425551

Symptom relief Sponsor: Naval Hospital, Athens Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a gentle laser (micropulse) on 30 people with dry eye from meibomian gland dysfunction. The laser targets tiny blood vessels on the eyelid edge to reduce inflammation and improve tear quality. Researchers measured tear stability and symptom scores to see if the treatment helps.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

30 people

The number who actually took part.

Started

Dec 2022

Finished

Jul 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria were: * chief complaint of at least one of the following symptoms: dryness, foreign-body sensation, burning, and tearing for 3 months * diagnosis of DED secondary to MGD with eyelid margin telangiectasias in both eyes * a baseline Ocular Surface Disease Index (OSDI) score ≥ 40 * tear break-up time (TBUT) ≤ 5 seconds * corneal fluorescein staining ≥ 6 as per the National Eye Institute (NEI) grading scale for corneal staining. Exclusion criteria were: * history of ocular trauma or surgery * use of any treatment for DED or MGD other than artificial tears within the past 3 months * active allergy, infection, or inflammatory disease at the ocular surface unrelated to DED or MGD * lacrimal drainage system anomalies * contact lens wear * use of any systemic or topical anti-inflammatory medicine

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dry eye are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

dry eye syndrome Meibomian Gland Dysfunction telangiectasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dry eye Dry eye syndromes Meibomian gland dysfunction

Contacts and locations

Locations

  • First Department of Ophthalmology, National and Kapodistrian University of Athens, Athens, Greece

    Athens, Greece

  • Naval Hospital of Athens

    Athens, 11521, Greece

More trials for these conditions

Other studies related to the condition(s) this trial covers.